// App-Quantinova.ai

TPS2634 : Patient preference trial comparing capecitabine and S-1 in metastatic breast cancer patients.

Researchers

Presenter

  • Daigo Yamamoto

Principal Investigators

  • Satoru Iwase

  • Hiroki Odagiri

  • Keisuke Ariyoshi

  • Kaoru Kitamura

  • Takuhiro Yamaguchi

  • Yu Tsubota

  • Takashi Kawaguchi

Medical Centers

  • Fukuoka Nagumo Clinic, Fukuoka, Japan

  • Department of Surgery, Kansai Medical University, Moriguchi, JapanSugery, Hirosaki University, Hirosaki, JapanDepartment of Palliative Medicine, University of Tokyo Hospital, Tokyo, Japan

  • Kansai Medical University, Hirakata, Osaka, Japan.

  • Division of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi, Japan

  • Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Depression

  • Anxiety

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Capecitabine

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • NA

Study Id's

  • UMIN000013045

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved